Similarly to SGLT2i, glucagon-like peptide-1 receptor agonists (GLP1-RAs) improve cardiovascular outcomes, especially in metabolic patients, with or without established cardiovascular disease [20,21,22,23]. The gene discussed is GLP1R; the disease is cardiovascular disorder.